Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1469552

Trends of Antiseizure Medication Utilization Among Pregnant People in Four Canadian Provinces from 1998 to 2023; A Study from the Canadian Mother-Child Cohort Active Surveillance Initiative (CAMCCO)

Provisionally accepted
  • 1 College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
  • 2 Research Center, CHU Sainte-Justine, Montreal, Quebec, Canada
  • 3 Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada
  • 4 College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
  • 5 Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
  • 6 Canadian VIGOUR Center, University of Alberta, Edmonton, Alberta, Canada
  • 7 Department of Psychiatry, College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
  • 8 Departments of Medicine and Epidemiology, University of Washington, Seattle, United States
  • 9 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
  • 10 Section of Neurology, Max Rady College of Medicine, Winnipeg, Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada
  • 11 Department of Pediatrics and Child Health, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
  • 12 Manitoba Centre for Health Policy, Winnipeg, Manitoba, Canada
  • 13 Alberta Health Services, Edmonton, Canada
  • 14 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • 15 Children’s Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada

The final, formatted version of the article will be published soon.

    Background: Epilepsy management during pregnancy is crucial for both the mother and fetus.The use of antiseizure medications (ASMs) during pregnancy requires careful consideration due to their potential effects on maternal and fetal health. Methods: This study analyzed trends in ASMs use among pregnant people in four Canadian provinces over 20 years (Manitoba, Saskatchewan, Alberta, and Quebec). Descriptive statistics were utilized to examine the characteristics of the population, with the frequency and patterns of ASM use estimated throughout each trimester. Linear regression models were developed to analyze yearly patterns of ASM utilization for the overall study population, as well as for people with and without epilepsy. Results: Among 1,317,141 pregnant individuals across four provinces, 0.7% had epilepsy. Of the total pregnancies, 1.7% (n = 22,783) were exposed to ASMs, comprising 4,392 from pregnant people with epilepsy (PPWE) and 18,391 from those without epilepsy (PPWOE).Results demonstrated varying trends in ASM usage between provinces, with an overall increase in usage among people without epilepsy in Manitoba, Saskatchewan, and Alberta. ASM use among PPWOE surged significantly in Manitoba (24.2 to 149.1 per 10,000 pregnant people), Saskatchewan (29.4 to 107.0 per 10,000), and Alberta (65.7 to 241.7 per 10,000) (p < 0.05). In Alberta, PPWE's ASM exposure also rose, from 23.6 in 2008 to 43.0 per 10,000 pregnant people in 2021, while Quebec witnessed a decrease from 59.2 in 1998 to 45.5 per 10,000 pregnancies in 2015. Analysis of ASM use by trimester illustrated a substantial decline among PPWOE from 365 days pre-pregnancy to the third trimester in all provinces. ASM utilization by drug class showcased significant shifts, with second-generation ASMs experiencing a notable rise.Carbamazepine, once prominent, declined, making way for lamotrigine. Regional variations underscore diverse preferences, such as clonazepam's sustained popularity in Manitoba and Quebec. Conclusions: The study identified increasing trends in ASM use, particularly the increased use of second-generation ASMs, and differences in prescription patterns for pregnant individuals with and without epilepsy. These findings reveal changing ASM use patterns, including increased second-generation ASM use and regional disparities, providing valuable insights into real-world prescription practices.

    Keywords: Pregnancy, antiseizure medications, Epilepsy, Drug Utilization, Prescriptions, Monotherapy, polytherapy, Canada

    Received: 24 Jul 2024; Accepted: 31 Oct 2024.

    Copyright: © 2024 Peymani, Bérard, Winquist, Kaul, Sheehy, Lavu, Leong, Falk, Delaney, Kowalec, Ng, Ruth, Aboulatta, Alessi-Severini, Dragan, Derksen, Barrett, Shams and Eltonsy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Sherif Eltonsy, College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.